Humacyte
$1.02
423
+$0.02+2.2% Monday 21:00
Statistics
Day High
1.02
Day Low
0.95
52W High
4.5
52W Low
0.91
Volume
3,079,327
Avg. Volume
4,902,498
Mkt Cap
191.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
26MarExpected
Expected EPS
-0.13165
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-297.4MNet Income
Analyst Ratings
$8.50Average Price Target
The highest estimate is 25.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow HUMA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Mimedx Group
MDXG
Mkt Cap1.13B
Precigen
PGEN
Mkt Cap1.46B
Fate Therapeutics
FATE
Mkt Cap155.7M
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Vericel
VCEL
Mkt Cap1.77B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Editas Medicine
EDIT
Mkt Cap276.95M
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
About
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Show more...
CEO
Dr. Laura E. Niklason M.D., Ph.D.
Employees
218
Country
US
ISIN
US44486Q1031
Listings
0 Comments
Share your thoughts
FAQ
What is Humacyte stock price today?▼
The current price of HUMA is $1.02 USD — it has increased by +2.2% in the past 24 hours. Watch Humacyte stock price performance more closely on the chart.
What is Humacyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Humacyte stocks are traded under the ticker HUMA.
Is Humacyte stock price growing?▼
HUMA stock has fallen by -0.97% compared to the previous week, the month change is a +4.62% rise, over the last year Humacyte has showed a -76.28% decrease.
What is Humacyte market cap?▼
Today Humacyte has the market capitalization of 191.02M
When is the next Humacyte earnings date?▼
Humacyte is going to release the next earnings report on March 26, 2026.
What were Humacyte earnings last quarter?▼
HUMA earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.15 USD resulting in a +27.17% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Humacyte revenue for the last year?▼
Humacyte revenue for the last year amounts to 0 USD.
What is Humacyte net income for the last year?▼
HUMA net income for the last year is -297.4M USD.
How many employees does Humacyte have?▼
As of February 03, 2026, the company has 218 employees.
In which sector is Humacyte located?▼
Humacyte operates in the Health Care sector.
When did Humacyte complete a stock split?▼
Humacyte has not had any recent stock splits.
Where is Humacyte headquartered?▼
Humacyte is headquartered in Durham, US.